Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Busby

Showing results (41-50 of 110) with videos related to

Pageof 11
Sort By:
BMJ Open|October 5, 2013
A pragmatic randomised controlled trial of 'PhysioDirect' telephone assessment and advice services for patients with musculoskeletal problems: economic evaluationSandra Hollinghurst, Joanna Coast, John Busby, et al.
The Lancet. Respiratory Medicine|May 10, 2021
The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational studyP Jane McDowell, Sarah Diver, Freda Yang, et al.
British Journal of Cancer|November 19, 2022
UK Biobank: a globally important resource for cancer researchMegan C Conroy, Ben Lacey, Jelena Bešević, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 21, 2022
Corticosteroid Responsiveness Following Mepolizumab in Severe Eosinophilic Asthma-A Randomized, Placebo-Controlled Crossover Trial (MAPLE)Freda Yang, John Busby, Liam G Heaney, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 15, 2017
The Diagnosis of Urinary Tract Infection in Young Children (DUTY) Study Clinical Rule: Economic EvaluationWilliam Hollingworth, John Busby, Christopher C Butler, et al.
Thorax|December 10, 2020
Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic eraDavid J Jackson, John Busby, Paul E Pfeffer, et al.
ERJ Open Research|January 21, 2026
Real-world effectiveness of biologic therapies in severe asthma patients ineligible for phase 3 randomised controlled trials of biologics: an analysis from the UK Severe Asthma RegistryPaul E Pfeffer, Jola Karaj, Thomas Brown, et al.
The Journal of Allergy and Clinical Immunology. Global|July 29, 2024
Impact of comorbidities on EQ-5D quality-of-life index in severe asthmaPaul E Pfeffer, Thomas Brown, Rekha Chaudhuri, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 22, 2018
Model for Identifying Individuals at Risk for Esophageal AdenocarcinomaAndrew T Kunzmann, Aaron P Thrift, Chris R Cardwell, et al.
Thorax|April 8, 2025
Incidence and prevalence of asthma, chronic obstructive pulmonary disease and interstitial lung disease between 2004 and 2023: harmonised analyses of longitudinal cohorts across England, Wales, South-East Scotland and Northern IrelandHannah Whittaker, Adriana Kramer Fiala Machado, Sara Hatam, et al.
Pageof 11

Showing results (41-50 of 110) with videos related to

Sort By:
Pageof 11
BMJ Open|October 5, 2013
A pragmatic randomised controlled trial of 'PhysioDirect' telephone assessment and advice services for patients with musculoskeletal problems: economic evaluationSandra Hollinghurst, Joanna Coast, John Busby, et al.
The Lancet. Respiratory Medicine|May 10, 2021
The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational studyP Jane McDowell, Sarah Diver, Freda Yang, et al.
British Journal of Cancer|November 19, 2022
UK Biobank: a globally important resource for cancer researchMegan C Conroy, Ben Lacey, Jelena Bešević, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 21, 2022
Corticosteroid Responsiveness Following Mepolizumab in Severe Eosinophilic Asthma-A Randomized, Placebo-Controlled Crossover Trial (MAPLE)Freda Yang, John Busby, Liam G Heaney, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 15, 2017
The Diagnosis of Urinary Tract Infection in Young Children (DUTY) Study Clinical Rule: Economic EvaluationWilliam Hollingworth, John Busby, Christopher C Butler, et al.
Thorax|December 10, 2020
Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic eraDavid J Jackson, John Busby, Paul E Pfeffer, et al.
ERJ Open Research|January 21, 2026
Real-world effectiveness of biologic therapies in severe asthma patients ineligible for phase 3 randomised controlled trials of biologics: an analysis from the UK Severe Asthma RegistryPaul E Pfeffer, Jola Karaj, Thomas Brown, et al.
The Journal of Allergy and Clinical Immunology. Global|July 29, 2024
Impact of comorbidities on EQ-5D quality-of-life index in severe asthmaPaul E Pfeffer, Thomas Brown, Rekha Chaudhuri, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 22, 2018
Model for Identifying Individuals at Risk for Esophageal AdenocarcinomaAndrew T Kunzmann, Aaron P Thrift, Chris R Cardwell, et al.
Thorax|April 8, 2025
Incidence and prevalence of asthma, chronic obstructive pulmonary disease and interstitial lung disease between 2004 and 2023: harmonised analyses of longitudinal cohorts across England, Wales, South-East Scotland and Northern IrelandHannah Whittaker, Adriana Kramer Fiala Machado, Sara Hatam, et al.
Pageof 11